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LETTERS TO THE EDITOR“Global vascular guidelines on the
management of chronic limb-threatening
ischemia” is an important milestone, but
some questions remainWe have read with great interest the very much needed
and expected guidelines on the management of chronic
limb-threatening ischemia (CLTI).1 Knowledge on how to
serve best the CLTI patients lacked joint expert update
and guidelines set forward by the Authors deserve
deep appreciation.
However, in our opinion, some of the recommendations
provided by the authors require further refinement.
Our first concern is the way the global limb anatomic
staging grade is performed for infrapopliteal (IP) arteries.
As the authors rightfully state, in very advanced femoro-
popliteal disease, some of the patent IP arteries may not
become opacified when the dye is injected at the level of
proximal arteries. It may be necessary to recanalize the
femoropopliteal segment first and inject the dye into
the distal popliteal artery to obtain a candid picture of
the IP arteries. Accordingly, IP global limb anatomic stag-
ing evaluation based on preprocedural angiographic im-
aging may overestimate the grade and even lead to an
erroneous conclusion that the patient is technically un-
suitable for any revascularization.
Also, some aspects of the presented concept of the IP
target artery pathway (TAP) revascularization may be
difficult to accept. The article states that the “TAP is
generally selected on the basis of the least diseased
crural artery providing runoff to the foot.” The fibular
artery is often the least affected IP vessel and usually pro-
vides some branches to the foot. A guideline might be
understood the way that the fibular artery should be
preferentially chosen for IP revascularization. Most pa-
tients with CLTI, however, feature forefoot ischemic le-
sions and, in these cases, the hemodynamic effects of
fibular artery revascularization will in most instances
not equate with tibial artery revascularization. Usually,
the diameter of the distal tibial artery is 2.5 mm. The
cross-sectional area of a 2.5 mm tube equals almost
three 1.5-mm tubes, more than six 1.0-mm tubes, and
twenty-five 0.5-mm tubes. Because distal branches of
the fibular artery are usually scarce and relatively narrow,
even optimal revascularization of the fibular artery might
be insufficient to provide sufficient blood flow to the
ischemic forefoot. We acknowledge the fact of various
approaches to foot revascularization. Additionally, the
available evidence is not adequate to back any one of
these. We only stress the fact that hemodynamics is
essential, and that the number and size of distal fibular
branches should be taken into account when choosing
the TAP in forefoot lesions.
Finally, how should we proceed if we fail to recanalize
the IP artery initially chosen to become the IP part of
the TAP, but succeed to open another artery and348eventually provide sufficient inflow to the foot arteries?
It is quite frequent that we are unable to recanalize our
first-choice artery, but can recanalize our second or
even third choice IP artery, although in our initial assess-
ment we thought they were less suitable for recanaliza-
tion for being more diseased or with lesions more
challenging to cross. Should we then regrade the patient
or stick to the primary grade?
We think this issue requires additional clarification to
obtain comparable results between different centers
involved in endovascular revascularization.
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https://doi.org/10.1016/j.jvs.2019.08.267ReplyWe thank the correspondents for their review of the
Global Vascular Guidelines document and their thought-
ful questions on the application of the new anatomic
staging system (Global Limb Anatomic Staging System
[GLASS]) proposed for chronic limb-threatening
ischemia (CLTI). Indeed, the authors of the guideline
acknowledge the need for prospective critical evaluation
of the new staging systems (both clinical and anatomic)
to improve data comparisons and evidence-based treat-
ment approaches. In the case of GLASS, the key element
in this advance is the integration of lesion complexity
across the limb from groin to foot, which we believe is
central to the selection of an optimal revascularization
strategy in CLTI.
Regarding the specific questions raised, the authors
first point out the potential challenges associated with
optimal angiographic imaging to define the tibial and
pedal target vessels, particularly in the presence of prox-
imal disease. In this regard, angiographic techniques are
not standardized in relation to catheter position, contrast
material volume, use of power injection, timing, projec-
tions, image resolution, and capture. We are unable to
make specific recommendations on these important
elements. However, the guideline points out that
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foot is a fundamental prerequisite for defining candidacy
and strategies for revascularization in CLTI. This implies
that the imaging must be sufficient for the evaluation
of open bypass options. In our opinion, this seldom
would require beginning with a femoropopliteal inter-
vention as patent distal targets are filled from collaterals.
There is a note of concern that the era of endovascular
intervention has potentially led to deterioration in the
quality of diagnostic arteriography.
The selection of the primary target artery pathway (TAP)
in each case is based on both the anatomy and clinical
circumstances at hand. As the guideline mentions, it
may often be the least diseased outflow vessel, but the
TAP may also be selected on the basis of preference for
a specific angiosome or other technical factors. There
are no well-established criteria in this regard for either
open or endovascular intervention. It is, however, worth
pointing out that open bypass to the peroneal artery
has a substantial track record of success in diabetic
limb salvage, including healing of transmetatarsal ampu-
tations. More evidence is needed to define optimal TAP
selection and also the potential role of multivessel revas-
cularizations in CLTI.
The last important point raised relates to choosing a sec-
ondary TAPwhen theprimary target couldnotbe success-
fully treated. This is really a question for data reporting and
outcomes comparisons. In prospective studies, both the
primary artery attempted and the secondary artery
treated should be reported for analysis, in the first case
because the incidence of technical failure is important
to document and helps to validate GLASS infrapopliteal
grades and stages. However, downstream clinical out-
comes shouldbe comparedon thebasis of the revascular-
izationasperformed. Ifmore thanone infrapopliteal artery
is treated, the interventionalist should document which
was considered the primary target for the case.Michael S. Conte, MD
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https://doi.org/10.1016/j.jvs.2019.09.025Transcarotid artery revascularization is
moving from its infancy to childhoodTranscarotid artery revascularization (TCAR) has
received its U.S. Food and Drug Administration approval,
has garnered additional substantiation by the study of
Kashyap et al,1 and thus is moving from its infancy to
childhood phase with real-world results on the horizon.
The authors are to be congratulated on expanding our
present knowledge in the area of carotid intervention.
However, there is concern that the safety and effective-
ness outcomes associated with TCAR could decline as
it moves into the real world. Some of these concerns
center on the strict inclusion and exclusion criteria,
medication adherence, and device learning curve.
Importantly, the low event rates for the Kashyap study
are comparable to those found in the pivotal Safety
and Efficacy Study for Reverse Flow Used During Carotid
Artery Stenting Procedure (ROADSTER)2 and also for a
much larger Society for Vascular Surgery Vascular Qual-
ity Initiative containing 1182 TCAR cases.3 The early re-
sults shared by Kashyap and colleagues suggest that
the TCAR procedure is a carotid intervention that can
be mastered in a very short time (ie, five or fewer training
cases), and it has been found to lower the risk of cranial
nerve injury.
As we move forward and the news of the device begins
to fade and less attention is paid to trial adherence, will
the low event rates remain? Indeed, Paraskevas et al4
likewise have proclaimed a similar concern regarding
the discordance between randomized trials and
real-world results within the field of vascular surgery.
Moreover, there are ongoing concerns about the appro-
priateness of TCAR interventions in patients with severe
or occluded contralateral lesions, whereas these patients
were excluded in the experimental trials.2 Although cra-
nial nerve injury was lower than the 6% reported by the
Carotid Stenting Trialists’ Collaboration,5 there remains
the possibility of lymphatic leak on the left side from
injury to the thoracic duct or vagus nerve injury.
So, despite TCAR’s having successfully survived infancy,
awareness, caution, and expertly deployed mitigating
countermeasures will enhance this promising therapy’s
likelihood of a promising childhood.
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